Primary Mammary Angiosarcoma: Literature Review

Dhirendra Nath Soren ¹, Gopalakrishnan Gunasekaran ², Debasis Naik ³, Gouranga Charan Prusty ⁴, Sakthivel Chinnakkulam Kandhasamy ⁵

1. General Surgery, Veer Surendra Sai Institute of Medical Sciences and Research, Burla, IND 2. Surgical Gastroenterology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, IND 3. General Surgery, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, IND 4. Pathology, Pandit Raghunath Murmu Medical College and Hospital, Baripada, IND 5. Surgery, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, IND

Corresponding author: Debasis Naik, debasismbbs@gmail.com

Abstract

Angiosarcomas of the breast are extremely rare, highly aggressive tumors of vascular origin comprising 0.04% of all malignant neoplasms of the breast. They can be classified into primary mammary angiosarcomas and cutaneous (secondary) angiosarcomas. Primary angiosarcomas, owing to their unusual clinical presentation, are diagnosed late. In addition, the available literature to date lacks sufficient evidence to establish standard treatment guidelines for this group of tumors, thereby resulting in poor prognosis. In medical database, most available papers concern secondary angiosarcomas, with only a few case reports of primary angiosarcomas. The aim of this paper is to review what is known hitherto about the presentation, diagnostic tools, and therapeutic modalities for primary mammary angiosarcomas.

Categories: Pathology, General Surgery, Oncology

Keywords: primary mammary angiosarcoma, cutaneous angiosarcoma, blood lakes, cd31, cd34, wide local excision, mastectomy, factor viii

Introduction And Background

Primary angiosarcomas of the breast are extremely rare, highly aggressive tumors of vascular origin accounting for 0.04% of all malignant neoplasms of the breast [1]. Angiosarcomas of the breast can be classified into primary angiosarcomas, arising de novo, and cutaneous (secondary) angiosarcomas, developing as a consequence of previous breast cancer treatment (e.g., prior postoperative radiotherapy and/or long-standing lymphedema following treatment for breast cancer, known as Stewart-Treves syndrome). Primary mammary angiosarcomas arise within the breast parenchyma with infrequent invasion of the skin [2]. Owing to its unusual clinical presentation and rarity, the diagnosis is usually delayed, thereby resulting in a poorer prognosis. In addition, in medical databases, most available articles report secondary angiosarcomas, with only a few case reports of primary mammary angiosarcomas. We therefore attempt to review the literature, which will help in clarifying what is known about primary breast angiosarcomas hitherto.

Review

Epidemiology

Mammary angiosarcomas are extremely rare, with malignant fibrous histiocytoma, fibrosarcoma, and liposarcoma being the more common histological subtypes of breast sarcomas. Only around 20% of the mammary angiosarcomas are primary angiosarcomas, with an incidence of around 17 new cases per million women [3].

Etiology

Etiology is unknown. This malignant tumor occurs primarily in young women, with 6-12% of the cases occurring while they are gestating, suggesting a hormonal effect [4,5]. Nonetheless, estrogen receptor positivity is so uncommon in the reported cases that the hormonal dependency of angiosarcoma is still undetermined [6].

Clinical presentation

Primary angiosarcomas are usually observed in women in the third to fifth decade of life, presenting either with a sense of fullness of breast or an insidious onset, rapidly growing painless palpable mass (Figure 1). Tumors that are large and superficial often present with purplish-blue discoloration of the overlying skin [7-9]. Large masses have also been reported, steering the consumption of platelets and clotting factors and the hemorrhagic manifestations of hemangioma thrombocytopenia syndrome [10,11].

Received 05/15/2020
Review began 06/06/2020
Review ended 06/06/2020
Published 06/12/2020

© Copyright 2020

Soren et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

How to cite this article

Soren D, Gunasekaran G, Naik D, et al. (June 12, 2020) Primary Mammary Angiosarcoma: Literature Review. Cureus 12(6): e8589. DOI 10.7759/cureus.8589

FIGURE 1: Clinical presentation of mammary angiosarcoma, presenting with a rapidly increasing painless breast mass.

Diagnosis

Though there is some evidence that mammography and ultrasonography may raise a suspicion, there are no specific pathognomonic features that can point toward this diagnosis. Mammographic findings include an ill-defined mass without calcification with associated overlying skin thickening. Ultrasound may reveal a heterogeneous mass, with hypervascularity demonstrable on color Doppler [9]. MRI is the radiological investigation of choice for characterizing and diagnosing breast angiosarcomas. This is due to its characteristic ability of proper evaluation of the regional extent of the tumor and envisioning the vascular nature of the lesion. The tumor appears as a heterogeneous mass with hypointensity on T1-weighted and hyperintensity on T2-weighted images, with high-grade tumors usually exhibiting swift enhancement with washout kinetics and lower grade tumors exhibiting persistent or plateau enhancement kinetics. High-grade tumors can also exhibit localized areas of hyperintensity on T1-weighted images, reflecting hemorrhage or vascular lakes [12]. In addition, CT of the thorax may be useful to look for lung metastasis.

Preoperative histological diagnosis of mammary angiosarcomas by fine needle aspiration cytology (FNAC) or needle biopsy is usually difficult. Chen et al. noted a false negative rate of 37% with needle biopsy [4]. Larger core biopsies might aid in the accurate diagnosis by furnishing a larger sample, but such a macrobiopsy is usually challenging to perform, considering the highly vascular nature of these tumors. Pathologically, breast angiosarcomas are stratified into three groups as per the division by Donnell et al. [13]. Group I (low grade) angiosarcomas contain inter-anastomosing vascular channels coursing through the breast lobules and surrounding ducts. These channels are lined by hyperchromatic endothelial cells and exhibit minimal endothelial tufting. Group II (intermediate grade) tumors in addition to the features of low-grade angiosarcomas exhibit papillary formation with mitoses with or without solid or spindle cell foci. Hemorrhage and necrosis are absent. Group III (high grade) tumors differ from group II by demonstrating prominent endothelial tufting, papillary formation, and solid and spindle cell foci with numerous mitosis, with blood lakes and necrosis (Figures 2-4). The less well-differentiated features of group II and III tumors tend to be located within rather than in the periphery, requiring a thorough review of all sections to stratify these tumors appropriately [13]. This also explains the reason behind the majority of needle biopsies yielding negative results.

FIGURE 2: Gross specimen following wide local excision showing a lobulated mass, cut section of which shows areas of hemorrhage.

FIGURE 3: Histopathology showing the presence of dilated and thrombosed blood vessels surrounded by neoplastic cells with areas of hemorrhage (blood lakes) (100x, H&E).

H&E, hematoxylin and eosin stain

FIGURE 4: Histopathology showing the presence of freely anastomosing vascular channels lined by atypical endothelial cells (400x, H&E).

H&E, hematoxylin and eosin stain

Although histopathological findings are conclusive, various immunochemical stains for endothelial markers such as CD31, CD34, and factor VIII (von Willebrand factor), and other markers for sarcoma help in finalizing the diagnosis. Amidst these, the most sensitive and specific marker of angiogenic proliferation is CD31 [14-16].

Treatment

Due to the rarity of this tumor, published reports on patients with primary mammary angiosarcoma are limited, making it difficult to establish therapeutic recommendation between total mastectomy and breast-conserving treatment. Complete surgical excision is the key, with a preference given to total mastectomy. Breast-conserving treatment is usually employed in small tumors, where it can serve to be the definitive method of surgical treatment if adequate negative margins can be obtained [10]. Since the tumor metastasizes through the hematogenous route as a rule, lymph node involvement is extremely rare. Hence, routine axillary lymph node dissection is unnecessary unless clinical and intra-operative findings such as enlarged axillary lymph nodes necessitate a radical approach [4].

Owing to mixed results found in various series, there is no international consensus on chemotherapy regimens to date that can be employed in mammary angiosarcomas in the adjuvant setting. The Italian Randomized Cooperative Trial by Frustaci et al. revealed significant improvement in both disease-free survival (DFS) and overall survival (OS) using an adjuvant regimen based on epirubicin plus ifosfamide for adult soft tissue sarcomas [17]. But Sher et al. did not find any survival benefit using anthracycline-ifosfamide or gemcitabine-taxane combination chemotherapy regimens in primary breast angiosarcomas. However, given the activity of cytotoxic chemotherapy in metastatic mammary angiosarcomas, adjuvant chemotherapy should be unquestionably advocated in patients with high risk localized breast angiosarcomas [18].

Adjuvant radiotherapy has been used in breast sarcomas with the aim of enhancing both locoregional control after surgery as well as the OS. This treatment modality is particularly valuable in patients with microscopically positive (R1) margins. In the retrospective study conducted by Johnstone et al. to determine the efficacy of adjuvant radiotherapy in primary mammary sarcomas, it was found that radiotherapy provided excellent local control with an actuarial five year DFS and OS of 68% and 66%, respectively [19]. Even though the result seems to be encouraging, this lacks validity due to the small sample size.

Prognosis

Prognosis of primary mammary angiosarcoma such as other soft tissue sarcomas is dependent on tumor size, grade, and resection margin status [16]. While the interface between tumor grade and margin status with prognosis has been clearly established, the literature presents contrasting opinions regarding the relationship between tumor size and prognosis. Authors like Rosen et al., Bousquet et al., and Blanchard et al. in their observations found no association between the primary tumor size and the DFS or OS [5,20,21]. However, authors like Sher et al. and Adem et al. found contradictory results in their series of primary

mammary sarcomas, proving the association of tumor size with DFS and OS [18,22]. Zelek et al. in their study on prognostic factors for primary breast angiosarcomas also found a strong association between the tumor size and DFS, without any significant influence on OS [23].

Conclusions

Primary angiosarcoma of breast is an extremely rare and aggressive malignancy affecting young females, usually presenting with a rapidly growing painless mass. When breast imaging shows a large vascular mass, odds of angiosarcoma should be considered. Diagnosis should be confirmed with core needle biopsy, though it is associated with a significant false-negative rate. Complete surgical excision is the key, with adjuvant chemotherapy in high-risk patients and radiotherapy particularly valuable in cases with microscopically positive margins, to improve the locoregional control and survival. Despite the aggressive multimodal therapy, prognosis remains poor.

Additional Information

Disclosures

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Acknowledgements

We are thankful to the post-graduate students of the Department of Surgery, JIPMER, Puducherry, and VIMSAR, Burla, for their contribution.

References

- Hodgson NC, Bowen-Wells C, Moffat F, Franceschi D, Avisar E: Angiosarcomas of the breast: a review of 70 cases. *Am J Clin Oncol*. 2007, 30:570-573. [10.1097/COC.0b013e3181131d62](https://doi.org/10.1097/COC.0b013e3181131d62)
- Nascimento AF, Raut CP, Fletcher CD: Primary angiosarcoma of the breast: clinicopathologic analysis of 49 cases, suggesting that grade is not prognostic. *Am J Surg Pathol*. 2008, 32:1896-1904. [10.1097/PAS.0b013e318176dbc7](https://doi.org/10.1097/PAS.0b013e318176dbc7)
- Desbiens C, Hogue JC, Levesque Y: Primary breast angiosarcoma: avoiding a common trap. *Case Rep Oncol Med*. 2011, 2011:517047. [10.1155/2011/517047](https://doi.org/10.1155/2011/517047)
- Chen KTK, Kirkegaard DD, Bocian JJ: Angiosarcoma of the breast. *Cancer*. 1980, 46:268-271. [10.1002/1097-0142\(19800715\)46:2<368::AID-CNCR2820460226>3.0.CO;2-E](https://doi.org/10.1002/1097-0142(19800715)46:2<368::AID-CNCR2820460226>3.0.CO;2-E)
- Rosen PP, Kimmel M, Ernsberger D: Mammary angiosarcoma: the prognostic significance of tumor differentiation. *Cancer*. 1988, 62:2145-2151. [10.1002/1097-0142\(19881115\)62:10<2145::aid-cnrcr2820621014>3.0.co;2-o](https://doi.org/10.1002/1097-0142(19881115)62:10<2145::aid-cnrcr2820621014>3.0.co;2-o)
- Antman KH, Corson J, Greenberger J, Wilson R: Multimodality therapy in the management of angiosarcoma of the breast. *Cancer*. 1982, 20:2000-2003. [10.1002/1097-0142\(19821115\)50:10<2000::aid-cnrcr2820501004>3.0.co;2-u](https://doi.org/10.1002/1097-0142(19821115)50:10<2000::aid-cnrcr2820501004>3.0.co;2-u)
- Scow JS, Reynolds CA, Degnim AC, Petersen IA, Jakub JW, Boughey JC: Primary and secondary angiosarcoma of the breast: the Mayo Clinic experience. *J Surg Oncol*. 2010, 101:401-407. [10.1002/jso.21497](https://doi.org/10.1002/jso.21497)
- Georgiannos SN, Sheaff M: Angiosarcoma of the breast: a 30 year perspective study with an optimistic outlook. *Br J Plast Surg*. 2003, 56:129-134. [10.1016/s0007-1226\(03\)00025-0](https://doi.org/10.1016/s0007-1226(03)00025-0)
- Yang WT, Hennessy BT, Dryden MJ, Valero V, Hunt KK, Krishnamurthy S: Mammary angiosarcomas: imaging findings in 24 patients. *Radiology*. 2007, 242:725-734. [10.1148/radiol.2423060163](https://doi.org/10.1148/radiol.2423060163)
- Kaklamanos IG, Birbas K, Syrigos KN, Vlachodimitropoulos D, Goutas N, Bonatsos G: Breast angiosarcoma that is not related to radiation exposure: a comprehensive review of the literature. *Surg Today*. 2011, 41:163-168. [10.1007/s00595-010-4341-x](https://doi.org/10.1007/s00595-010-4341-x)
- Bernathova M, Jaschke W, Pechlahner C, Zelger B, Bodner G: Primary angiosarcoma of the breast associated Kasabach-Merritt syndrome during pregnancy. *Breast*. 2006, 15:255-258. [10.1016/j.breast.2005.04.015](https://doi.org/10.1016/j.breast.2005.04.015)
- O'Neill AC, D'Arcy C, McDermott E, O'Doherty A, Quinn C, McNally S: Magnetic resonance imaging appearances in primary and secondary angiosarcoma of the breast. *J Med Imaging Radiat Oncol*. 2014, 58:208-212. [10.1111/1754-9485.12100](https://doi.org/10.1111/1754-9485.12100)
- Donnell RM, Rosen PP, Liberman PH, Kaufman RJ, Kay S, Braun DW, Kinne DW: Angiosarcoma and other vascular tumors of the breast: pathologic analysis as a guide to prognosis. *Am J Surg Pathol*. 1981, 5:629-642. [10.1097/0000478-198110000-00005](https://doi.org/10.1097/0000478-198110000-00005)
- Hart J, Mandavilli S: Epithelioid angiosarcoma: a brief diagnostic review and differential diagnosis. *Arch Pathol Lab Med*. 2011, 135:268-272.
- Folpe AL, Chand EM, Goldblum JR, Weiss SW: Expression of Fli-1, a nuclear transcription factor, distinguishes vascular neoplasms from potential mimics. *Am J Surg Pathol*. 2001, 25:1061-1066. [10.1097/0000478-200108000-00011](https://doi.org/10.1097/0000478-200108000-00011)
- Bennani A, Chbani L, Lamchahab M, et al.: Primary angiosarcoma of the breast: a case report. *Diagn Pathol*. 2013, 8:66. [10.1186/1746-1596-8-66](https://doi.org/10.1186/1746-1596-8-66)
- Frustaci S, Gherlinzoni F, De Paoli A, et al.: Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. *J Clin Oncol*. 2001, 19:1238-

1247. [10.1200/JCO.2001.19.5.1238](https://doi.org/10.1200/JCO.2001.19.5.1238)
18. Sher T, Hennessey BT, Valero V, et al.: Primary angiosarcomas of the breast . *Cancer*. 2007, 110:173-178. [10.1002/cncr.22784](https://doi.org/10.1002/cncr.22784)
19. Johnstone PA, Pierce LJ, Merino MJ, Yang JC, Epstein AH, Delaney TF: Primary soft tissue sarcomas of the breast: local-regional control with post-operative radiotherapy. *Int J Radiat Oncol Biol Phys*. 1993, 27:671-675. [10.1016/0360-3016\(93\)90395-c](https://doi.org/10.1016/0360-3016(93)90395-c)
20. Bousquet G, Confavreux C, Magne N, et al.: Outcome and prognostic factors in breast sarcoma: a multicenter study from the rare cancer network. *Radiother Oncol*. 2007, 85:355-361. [10.1016/j.radonc.2007.10.015](https://doi.org/10.1016/j.radonc.2007.10.015)
21. Blanchard DK, Reynolds CA, Grant CS, Donohue JH: Primary non phylloides breast sarcomas . *Am J Surg*. 2003, 186:359-361. [10.1016/S0002-9610\(03\)00269-1](https://doi.org/10.1016/S0002-9610(03)00269-1)
22. Adem C, Reynolds C, Ingle JN, Nascimento AG: Primary breast sarcoma: clinicopathologic series from the Mayo Clinic and review of the literature. *Br J Cancer*. 2004, 91:237-241. [10.1038/sj.bjc.6601920](https://doi.org/10.1038/sj.bjc.6601920)
23. Zelek L, Llombart-Cussac A, Terrier P, et al.: Prognostic factors in primary breast sarcomas: a series of patients with long-term follow-up. *J Clin Oncol*. 2003, 21:2583-2588. [10.1200/JCO.2003.06.080](https://doi.org/10.1200/JCO.2003.06.080)